Trevor Resnick, MD, an epileptologist with special qualifications in pediatric neurology at the Nicklaus Children's Hospital, gives an overview of Cannabidiol and its efficacy for patients with Lennox-Gastaut syndrome and Dravet syndrome.
Trevor Resnick, MD: Cannabidiol is a derivative of cannabis, and we don't really know the mechanism of action for Cannabidiol. It may be linked to the g-receptor protein or the -- we don't know. Nevertheless, it has been demonstrated to be effective in patients with Lennox-Gastaut syndrome and in patients with Dravet syndrome. And it's actually approved for seizures associated with those two syndromes. And, I think it's approved for above 2-years of age. And the effectiveness of Cannabidiol was gratifying in those 2 syndromes, and it's approved for those 2 syndromes.
And the major side-effects are fatigue, sleepiness, diaherra. And another, not specifically a side-effect, but it does have interaction with some medications that are commonly used for both those syndromes.